Veeva Systems

Overview

Veeva Systems is the default enterprise software platform for life sciences, spanning commercial CRM, promotional content, regulatory operations, clinical operations, quality, safety, HCP/HCO master data, and commercial analytics. It is not a narrow point solution; it is a platform-standardization decision about whether more of a manufacturer’s regulated operating workflows live on Vault or remain split across best-of-breed tools.

The near-term forcing function is Vault CRM migration. Legacy Salesforce-hosted Veeva CRM is moving to Veeva’s native Vault platform, with more than 125 customers live by March 2026 and end-of-support for the legacy CRM set for December 31, 2029. The strategic question is broader than CRM: Veeva is positioning Vault as the regulated system of record for commercial, medical, regulatory, quality, clinical, safety, and AI-enabled workflows. Veeva is not a hub services operator or a payer-data vendor; pair with category specialists where those operating jobs sit.

Platform Capability Model

The framework below standardizes how Rx Almanac evaluates data-technology-platforms capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Veeva Systems is evaluated as default enterprise software platform for life sciences, spanning commercial CRM, promotional content, regulatory operations, clinical operations, quality, safety, HCP/HCO master data, and commercial analytics.

Capability	Buyer should compare	Veeva Systems readout
Data aggregation and interoperability	Claims, EHR, CRM, pharmacy, provider, payer, and FHIR/API connectivity with normalization and identity resolution.	Strong / platform-led. Compass, Crossix, OpenData, Network, and Nitro create a commercial data layer, but global commercial data remains an IQVIA-heavy market outside Veeva’s strongest lanes.
Commercial analytics and patient finding	Targeting, segmentation, patient finding, provider analytics, referral leakage, and opportunity sizing.	Strong. Crossix and Compass connect patient-level analytics, media measurement, and Vault CRM workflows. Validate geography, refresh cadence, and data rights.
Workflow automation and CRM integration	Case workflows, field workflows, CRM, task automation, document handling, and operational queue management.	Core. Vault CRM migration is the defining event; buyers should treat it as commercial-ops reimplementation, not a simple software upgrade.
Provider, payer, and pharmacy network connectivity	Network reach across HCPs, payers, pharmacies, labs, health systems, and transaction endpoints.	Mixed. Veeva Network and OpenData are core HCP/HCO assets; payer and pharmacy workflow depth depends on use case and partner stack.
AI, NLP, and unstructured data extraction	Conversation intelligence, document AI, NLP extraction, predictive models, and model monitoring.	Emerging / important. Veeva AI Agents are embedded in Vault, but production value, pricing, and adoption depth should be diligence items.
Security, compliance, and governance	HIPAA, SOC2, data-use controls, auditability, consent, privacy, and regulated-workflow safeguards.	Core. Veeva’s regulated-workflow depth is a major reason customers accept higher switching cost and implementation burden.
Reporting, dashboards, and data delivery	Dashboards, exports, APIs, scheduled reporting, and downstream feeds to analytics or operating teams.	Strong where Vault is the system of record. Validate cross-system reporting if Salesforce, IQVIA, Medidata, SAP, or Snowflake remain primary systems.

Buyer Fit

• Best fit: Mid-size and large manufacturers that want a regulated platform spanning commercial, medical, R&D, quality, safety, content, and data workflows.
• Strongest launch-team fit: Manufacturers standardizing on Vault CRM, PromoMats, Crossix/Compass, Network/OpenData, or medical/commercial content workflows before or during launch.
• Where to be careful: Buyers that need best-of-breed EDC, highly customized Salesforce workflows, broad horizontal AI tooling, or non-U.S. commercial data depth should pressure-test Veeva against Medidata, Salesforce Life Sciences Cloud, IQVIA, and specialized analytics vendors.
• Commercial fit: Subscription pricing and enterprise implementation make Veeva an executive-sponsored platform decision. Smaller biotechs can still buy narrower modules, but scope control matters.
• Implementation fit: Treat every Vault CRM migration as process redesign plus validation, integration, data migration, training, and SI coordination.

Differentiators

• Vault platform gravity: Commercial, clinical, regulatory, quality, safety, and content workflows share the same regulated platform architecture.
• Forced CRM migration window: More than 125 customers are already live on Vault CRM, and the 2029 legacy sunset forces every incumbent Veeva CRM customer to make a platform decision.
• R&D and quality expansion: Development Cloud is now a major growth engine, especially where sponsors want RIM, eTMF, quality, safety, and clinical operations connected.
• Commercial data loop: Crossix, Compass, OpenData, Network, and Nitro give Veeva a route from patient/HCP signal to CRM execution and measurement.
• Regulated AI posture: Veeva AI Agents are embedded in existing Vault workflows, which is a stronger governance position than standalone AI tooling when compliance risk is high.

RFP Questions

• What buying motion applies for Veeva as an enterprise platform or as a narrower module, and what workflows will remain outside Vault?
• What is the migration plan from legacy Veeva CRM or Salesforce, including timeline, validation scope, data migration, offline/mobile behavior, and SI responsibilities?
• Which data assets are included in scope: Compass, Crossix, OpenData, Network, Nitro, IQVIA data feeds, or third-party sources?
• How will Veeva AI Agents be governed: model choice, usage pricing, human review, audit logs, MLR/safety escalation, and customer-specific data boundaries?
• Which responsibilities does Veeva recommend keeping best-of-breed tools such as Medidata, Salesforce, SAP, IQVIA, or Snowflake rather than consolidating?
• What proof exists for the specific therapeutic area, launch stage, geography, and user group we are buying for?

Recent Activity

• March 2026: Veeva reported FY2026 revenue of $3.195B and Q4 revenue of $836M.
• March 2026: Veeva announced 125+ customers live on Vault CRM and accelerated the legacy CRM end-of-support date to December 31, 2029.
• March 2026: Veeva acquired Ostro, adding AI-enabled brand engagement for life-sciences websites.
• December 2025: Veeva AI Agents became available for Vault CRM and PromoMats workflows.
• August 2025: Veeva and IQVIA settled long-running litigation and announced data-interoperability agreements.